Understanding Atopic Dermatitis: Barrier Breakdown, the Itch-Scratch Cycle, and the Rational Use of Topical Steroids
核心洞察
Atopic dermatitis (搜索) (AD) affects 10-15% of infants and 5-8% of adults in Japan, driven by filaggrin (搜索) gene mutations that structurally weaken the skin barrier.
The itch-scratch cycle is perpetuated by IL-31 (搜索) directly stimulating sensory nerves that extend abnormally into the epidermis, leading to lichenification and chronic inflammation.
Topical steroids remain the cornerstone of anti-inflammatory therapy; fears of systemic side effects are largely unfounded when used at appropriate strength, amount, and duration.
Atopic dermatitis (搜索) (AD) is neither "just rough skin" nor an immutable consequence of one's constitution. Rather, it begins with a genetically driven barrier abnormality that triggers excessive immune responses, creating a vicious cycle of itching and scratching that has been increasingly elucidated over the past two decades. Understanding this mechanism, experts emphasize, is the starting point for proper care and effective disease management.
AD is an allergic skin disease characterized by chronic, recurrent eczema and intense itching, seen in approximately 10-15% of infants and about 5-8% of adults in Japan. Diagnosis rests on three criteria: itchy eczema that follows a chronic or recurrent course, and the presence of an atopic predisposition—a genetic background of allergic constitution. The condition is further categorized into extrinsic AD, where allergic reactions to specific foods, dust mites, or pollen play a clear role, and intrinsic AD, where identifying allergens proves more challenging.
The Structural Failure at the Disease's Core
At the center of AD lies breakdown of the skin barrier. In healthy skin, the outermost stratum corneum is constructed like brickwork, with lipids such as ceramides organized around a critical protein called filaggrin (搜索). It is now well established that many individuals with AD carry mutations in the filaggrin gene, rendering their barrier structurally weak from the outset.
When this barrier collapses, two destructive processes unfold simultaneously. From the outside, antigens that should never penetrate—dust mite debris, pollen, food proteins, and Staphylococcus aureus—enter through gaps in the skin. From the inside, moisture escapes, and transepidermal water loss (TEWL) accelerates, intensifying dryness. This dual assault stimulates immune cells, particularly Th2 lymphocytes, triggering release of inflammatory mediators including IL-4 (搜索), IL-13 (搜索), and IL-31 (搜索).
Why the Itching Becomes Unstoppable
The pruritus of AD has a distinctive neurobiological basis. Under normal conditions, the C-fibers that sense itch reside in the dermis. However, as AD persists, sensory nerve endings extend abnormally into the epidermis, creating a hypersensitive state in which even trivial stimuli provoke intense itching. Compounding this, IL-31 (搜索) directly stimulates itch nerves, meaning that the more inflammation present, the more severe the itching becomes.
The decisive problem is the vicious cycle: scratching damages the skin, further degrading the barrier, which in turn worsens inflammation. Prolonged scratching leads to lichenification—skin that becomes thick and hard—which itself makes inflammation more likely to persist.
Age-Dependent Patterns and Worsening Factors
The distribution of AD rashes shifts characteristically with age. In infancy (up to approximately age two), lesions begin on the head, face, and cheeks before spreading to the trunk and limbs. During early childhood through school age, eczema concentrates in flexural areas such as the antecubital and popliteal fossae. From adolescence into adulthood, involvement can extend to the face, neck, décolleté, and entire body.
Worsening factors vary considerably between individuals. Environmental triggers—dust mites, mold, pollen, pet dander, cigarette smoke, sweat, dryness, and temperature fluctuations—interact complexly with dietary factors and with stress and sleep deprivation. In infants, eggs, milk, and wheat are common triggers, though their involvement often diminishes in older children and adults.
The Moisturizing Debate: Treatment Versus Prevention
While moisturizing is firmly established as effective for treating AD and preventing exacerbations, its role in primary prevention remains unsettled. An early domestic study (Horimukai 2014) reported that thorough moisturizing from the neonatal period reduced AD onset by approximately 30%, generating considerable attention. However, larger subsequent randomized controlled trials—the BEEP trial in the UK (Lancet 2020) and the PreventADALL trial in Norway (NEJM 2020)—failed to confirm that moisturizing healthy infants prevents disease onset. Current evidence therefore supports moisturizing as essential for barrier repair in established disease, but the expectation that moisturizing alone can prevent AD onset is not supported by rigorous scientific data.
Topical Steroids: Dispelling the Fear
Topical steroids remain the mainstay of anti-inflammatory pharmacotherapy. Yet clinicians frequently encounter patients who express fears: "If I keep using steroids, my skin will become thin," "I won't be able to stop," or "It will affect my internal organs." These concerns largely stem from confusion between the side effect profiles of oral or injectable steroids and those of topical preparations.
When topical steroids are used at appropriate strength, in the correct amount, and for the proper duration, side effects are predominantly limited to local issues—skin atrophy, telangiectasia, hypertrichosis—and most resolve upon dose reduction or discontinuation. Systemic effects such as elevated blood sugar or osteoporosis are considered unlikely within the scope of correct topical use. The harm of leaving inflammation untreated and allowing the barrier to continue breaking down, experts caution, far outweighs the risks of appropriate topical steroid therapy.
Key prescribing principles include: steroids are classified into five potency levels (I: strongest to V: weak), with selection based on site, age, and severity; the Finger Tip Unit (FTU)—approximately 0.5g from the index fingertip to the first joint—serves as a guide for application to an area equivalent to two adult palms; and absorption rates differ by anatomical site, with the face, scalp, and genitals requiring weaker preparations than the trunk.
Beyond Steroids: Expanding the Therapeutic Armamentarium
Several non-steroidal topical agents have emerged to supplement or replace steroids in specific contexts. Tacrolimus ointment (representative: Protopic®) suppresses inflammation through an immunomodulatory mechanism distinct from corticosteroids and is particularly useful for thin-skinned areas such as the face, neck, and skin folds due to its lower risk of skin atrophy. Initial burning or irritation typically subsides within days, and low-concentration pediatric formulations are available for use from age two.
More recently, delgocitinib (a JAK inhibitor topical, representative: Corectim®) and difamilast (a PDE4 inhibitor topical, representative: Moizerto®) have entered clinical practice, each with distinct mechanisms of action. For moderate to severe AD refractory to topical therapy alone, systemic options—including dupilumab (a biologic agent) and oral JAK inhibitors such as baricitinib, upadacitinib, and abrocitinib—have become available, though these require careful infection monitoring and regular specialist follow-up.
Proactive Therapy: Breaking the Relapse Cycle
A common and frustrating pattern in AD management is the cycle of "apply treatment, improve, stop, flare, reapply." The strategy designed to break this loop is proactive therapy. Even when AD skin appears calm, subclinical inflammation persists beneath the surface; abrupt treatment cessation invites immediate relapse.
The proactive approach involves first applying medication daily to thoroughly suppress inflammation during the acute phase, then gradually reducing frequency—from three times weekly, to twice weekly, to once weekly—with the ultimate goal of achieving a state maintainable with moisturizing alone. This gradual taper, rather than sudden discontinuation, constitutes the core of proactive therapy.
Managing Itch and Recognizing Emergencies
Oral antihistamines play a supplementary role in alleviating pruritus, though they should be viewed not as agents that eliminate itching entirely—since non-histaminergic pathways also contribute to AD-related itch—but as aids to ensure nighttime sleep and reduce scratching. Second-generation antihistamines with fewer sedative effects are generally preferred.
Patients and families must remain vigilant for signs of anaphylaxis. The appearance of throat discomfort, hoarseness, difficulty breathing, palpitations, sudden changes in facial complexion, severe abdominal pain, vomiting, lethargy, or loss of consciousness alongside hives warrants immediate emergency medical attention, as these may signal laryngeal edema or anaphylactic shock.
Treatment decisions—including choice of topical medication, application technique, tapering strategy, and use of newer agents—should always be pursued in close partnership with a dermatologist or pediatric specialist. Rather than avoiding necessary treatment based on fear of steroids, understanding and using them correctly protects both skin integrity and quality of life.